IMIDomics, a Vall d'Hebron spin-off, has completed a 14 million euros Series A financing round led by DNS Capital with additional investment from Bristol Myers Squibb, The Pritzker Organization, TAO Capital and others. 

It is one of the largest investment operations in the biomedicine and health sector in Catalonia to date.

IMIDomics was founded in Barcelona in 2015 by Sara Marsal, head of the Rheumatology Department at the Vall d’Hebron University Hospital and head of the Rheumatology Research Group at the Vall d'Hebron Research Institute (VHIR), and Richard M. Myers, president and Scientific Director at the HudsonAlpha Institute for Biotechnology (USA).

"IMIDomics is a successful case that should motivate researchers to transfer their knowledge to the industry creating an impact on the health and quality of life of society" says Joan Comella, CEO of  VHIR and member of the CataloniaBio & HealthTech board of directors.

The biotechnology company is focused on the discovery and development of new medicines for the treatment of immune-mediated inflammatory diseases (IMIDs): rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn’s disease, etc. IMIDomics utilises a proprietary digital bioinformatics platform that enables precision medicine for IMID patients and will lead to therapies that address needs not addressed by current medicines.

More information

Photo: Sara Marsal a l'Hospital Universitari Vall d'Hebron de Barcelona - © VHIR